ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » (0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM
Abstract Number: 0374
Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry
9:00AM-11:00AM
Abstract Number: 0366
Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis
9:00AM-11:00AM
Abstract Number: 0367
Adolescents and Young Adults Taking Methotrexate: Knowledge and Behaviours
9:00AM-11:00AM
Abstract Number: 0362
Adverse Childhood Experiences Are Associated with Disease Outcomes in Youth with Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0363
Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort
9:00AM-11:00AM
Abstract Number: 0371
Assessing Methotrexate Adherence in JIA Using Electronic Health Record-Linked Pharmacy Dispensing Data
9:00AM-11:00AM
Abstract Number: 0358
Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort
9:00AM-11:00AM
Abstract Number: 0378
Characteristics of Macrophage Activation Syndrome in Systemic JIA Patients Receiving Anakinra as First-line Treatment
9:00AM-11:00AM
Abstract Number: 0359
Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment
9:00AM-11:00AM
Abstract Number: 0370
Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 0379
Clinical Evolution of Patients Diagnosed of Juvenile Idiopathic Arthritis After the Transitional Care Consultation
9:00AM-11:00AM
Abstract Number: 0377
Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0349
Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care
9:00AM-11:00AM
Abstract Number: 0372
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial
9:00AM-11:00AM
Abstract Number: 0365
Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges
9:00AM-11:00AM
Abstract Number: 0360
Increasing the Etanercept Dose in Juvenile Idiopathic Arthritis Patients: Does It Help Reaching the Treatment Target? A Post-hoc Analysis of the Best4Kids Randomised Clinical Trial
9:00AM-11:00AM
Abstract Number: 0345
Jadas10- and cjadas10-based Disease Activity States for Psoriatic Arthritis, Enthesitis-related Arthritis, and Rf+ Polyarthritis
9:00AM-11:00AM
Abstract Number: 0355
Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0352
Musculoskeletal Ultrasound Findings in Children with Psoriasis
9:00AM-11:00AM
Abstract Number: 0351
Needs Assessment Survey of Critical Data Element Completion in Telemedicine Visits for Juvenile Idiopathic Arthritis in the Post-Pandemic Period
9:00AM-11:00AM
Abstract Number: 0354
Open-label Phase 3 Study of Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Pharmacokinetics, Effectiveness, Safety, and Immunogenicity over 252 Weeks
9:00AM-11:00AM
Abstract Number: 0373
Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study
9:00AM-11:00AM
Abstract Number: 0350
Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 0356
PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 0361
Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience
9:00AM-11:00AM
Abstract Number: 0364
Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 0368
Surveying Psychological Resilience and Pain in a Cross-Section of JIA Patients
9:00AM-11:00AM
Abstract Number: 0376
Switching Patterns of Biological and Targeted Synthetic Therapies in Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0348
The Use of Ruxolitinib for Improved Disease Control in Systemic Juvenile Idiopathic Arthritis (sJIA) and Recurrent Macrophage Activation Syndrome (MAS)
9:00AM-11:00AM
Abstract Number: 0347
Towards Effective Shared Decision Making – Development and Validation of a Prediction Model for Personalized Probabilities of Side Effects in the Initial Treatment of Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0369
Trajectory of Progression in Transition Readiness in Adolescents with JIA and jSLE
9:00AM-11:00AM
Abstract Number: 0375
Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR) Can Be Improved by Bi-lateral Alternating Stimulation Tactile (BLAST) Armbands
9:00AM-11:00AM
Abstract Number: 0346
Use, Safety and Persistence of Biosimilars in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events of Targeted Therapies in Rheumatic Diseases (BIOBADASER)
9:00AM-11:00AM
Abstract Number: 0353
Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods
9:00AM-11:00AM
Abstract Number: 0357
Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology